MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study

Hypoxic-ischemic brain injury (HIBI) is a disabling consequence of cardiopulmonary resuscitation, which has no direct treatment except supportive care. Many studies have used pharmacological agents to reduce or stop this disability. MLC901 is a traditional Chinese medicine showing neuroprotective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakdaman, Hossein, Gharagozli, Koroush, Karamiani, Faezeh, Shamsi Goushki, Maryam, Moini, Saman, Sobhanian, Ali, Maghsoudlu, Faeze, Esfandani, Akram, Hosseini, Mohammad Hossein, Amini Harandi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256404/
https://www.ncbi.nlm.nih.gov/pubmed/37335674
http://dx.doi.org/10.1097/MD.0000000000033914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256404/
https://www.ncbi.nlm.nih.gov/pubmed/37335674
http://dx.doi.org/10.1097/MD.0000000000033914

Ejemplares similares